EcoDrugPlus

Solute Carrier Family 22 Member 6

Ensembl ID : ENSMZEG00005018595
Gene Symbol: LOC101480908
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSMZEG00005015541
Gene Symbol: SLC29A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSMZEG00005027397
Gene Symbol: SLC29A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSMZEG00005005309
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSMZEG00005013731
Gene Symbol: SLC6A1
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSMZEG00005006987
Gene Symbol: SLC6A2
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSMZEG00005001594
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSMZEG00005014177
Gene Symbol: SLC6A9
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSMZEG00005026265
Gene Symbol: SLC9A3
4 Cross references
223 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSMZEG00005026248
Gene Symbol: SLC9A3
4 Cross references
223 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSMZEG00005012851
Gene Symbol: SSTR2
1 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSMZEG00005002937
Gene Symbol: SSTR2
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).